Charles River Labs Lifts 2026 Outlook on Q2 Beat as DSA Book-to-Bill Reaches Four-Year Peak
CRL sits 75% above its 52-week low of $144.26.
Summary
Charles River Laboratories posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, raised its full-year guidance, and highlighted the highest DSA book-to-bill in nearly four years, signaling a strengthening demand recovery.
Key Events · Earnings and Guidance · CRL
-
Q2 Revenue and EPS Beat
Driven by improving demand in DSA and better Manufacturing performance, revenue reached $1.00 billion (organic growth +0.1%) and non-GAAP EPS came in at $3.02, exceeding the prior outlook.
-
Full-Year Guidance Raised
Reflecting operational outperformance, 2026 organic revenue growth guidance was raised to 0.0%–1.0% (from -1.5% to -0.5%) and non-GAAP EPS to $11.15–$11.45 (from $10.80–$11.30).
-
DSA Book-to-Bill Hits 4-Year High
The Discovery and Safety Assessment segment recorded its highest net book-to-bill in nearly four years, indicating strengthening future revenue from both large pharma and biotech clients.
-
$100M Buyback at $174/Share
In Q2, 0.6 million shares were repurchased for $100 million at an average price of $174, well below the current $253, with $700 million remaining on the $1 billion authorization.
Analysis · CRL · Industrial Applications And Services
The strongest organic revenue growth since Q3 2023 and a raised full-year outlook signal that the demand recovery in Charles River's core DSA segment is gaining real traction. A net book-to-bill ratio at its highest in nearly four years points to building future revenue, while the $100 million buyback executed at an average price of $174—well below today's $253—adds a capital-return tailwind. The GAAP loss stems entirely from one-time divestiture charges, not operational weakness; non-GAAP EPS of $3.02 beat expectations and drove the guidance raise. With the stock trading near its 52-week high, the market has already priced in some optimism, but improving demand trends and the raised outlook provide fundamental support.
At the time of this filing, CRL was trading at $253.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $144.26 to $242.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.